[Skip to Content]
[Skip to Content Landing]
Views 105
Citations 0
Comment & Response
April 22, 2019

Ethical Review and Methodologic Innovation in Phase 1 Cancer Trials

Author Affiliations
  • 1Precision Methodologies, LLC, Seattle, Washington
JAMA Pediatr. 2019;173(6):609. doi:10.1001/jamapediatrics.2019.0811

To the Editor: The Viewpoint by Kimmelman et al1 frames the protection of pediatric phase 1 trial participants primarily as a question of what we may approve, rather than of what we can improve. It supposes that dangers to these participants arise chiefly from investigators’ and parents’ unreasonable optimism. Participant protection thus reduces to restraining these biased actors.

×